Saum Sutaria, M.D.

Yeah, cracked the door open for certain drugs. And I think we'll see how that goes. I mean, this is going to get mired in politics and lobbying and all kinds of things that you described. But if you step back and look at the big picture of where healthcare expenditures are going, let's just step back and actually look at just pharmaceutical expenditures rather than healthcare expenditures.

Yeah, cracked the door open for certain drugs. And I think we'll see how that goes. I mean, this is going to get mired in politics and lobbying and all kinds of things that you described. But if you step back and look at the big picture of where healthcare expenditures are going, let's just step back and actually look at just pharmaceutical expenditures rather than healthcare expenditures.

In addition to extraordinarily expensive drugs that have broad application like the GLPs, you have a broad range of orphan drugs that have been developed. Orphan drugs meaning for rare diseases for very few people, sometimes miraculous benefit for them at extraordinarily high price. It goes back to what you said about we want choice and access and we value saving money.

In addition to extraordinarily expensive drugs that have broad application like the GLPs, you have a broad range of orphan drugs that have been developed. Orphan drugs meaning for rare diseases for very few people, sometimes miraculous benefit for them at extraordinarily high price. It goes back to what you said about we want choice and access and we value saving money.

as Americans, that life more than what other countries may do in not saving that life and looking at it societally. And then the third thing is if you look at the pipeline of drugs for the next 10 years, I've done this, look at the PDUFA list or whatever at the FTA, the number of unique vaccines

as Americans, that life more than what other countries may do in not saving that life and looking at it societally. And then the third thing is if you look at the pipeline of drugs for the next 10 years, I've done this, look at the PDUFA list or whatever at the FTA, the number of unique vaccines

biologic infusible drugs in particular for autoimmune disease and cancer that are slated to go through the process and get approved which again not having seen the data it's hard to know whether they'll transform the care of those diseases or marginally improve them but if they get approved they'll be doing some benefits will create another massive explosion of drug costs here.

biologic infusible drugs in particular for autoimmune disease and cancer that are slated to go through the process and get approved which again not having seen the data it's hard to know whether they'll transform the care of those diseases or marginally improve them but if they get approved they'll be doing some benefits will create another massive explosion of drug costs here.

So the proportion that's going to hospitals and doctors relative to drugs, if you look out over the next decade, is poised to change again based upon the pipelines.

So the proportion that's going to hospitals and doctors relative to drugs, if you look out over the next decade, is poised to change again based upon the pipelines.

The inclusive version of the third where it's everything. And that's something we're going to have to grapple with.

The inclusive version of the third where it's everything. And that's something we're going to have to grapple with.

may not be designed to accommodate that cost without passing it back to employers and Medicare. And so then there's going to be a question again, what are we going to cover? What are we not going to cover? The way that healthcare costs are rising, we're being pushed to ask the supply side questions that the rest of the world has already asked and answered.

may not be designed to accommodate that cost without passing it back to employers and Medicare. And so then there's going to be a question again, what are we going to cover? What are we not going to cover? The way that healthcare costs are rising, we're being pushed to ask the supply side questions that the rest of the world has already asked and answered.

We're just grappling with it, and it's hard because of what we've talked about. We don't want to give up choice and access in the process of grappling with those decisions. For other countries, when new drugs come online, it's easy for them. They have an established framework.

We're just grappling with it, and it's hard because of what we've talked about. We don't want to give up choice and access in the process of grappling with those decisions. For other countries, when new drugs come online, it's easy for them. They have an established framework.

Yeah, it's an established framework. The citizens are used to that established framework. Here, we haven't established the framework. I mean, this goes to the point of it's not obvious that we have national health goals, a different topic. And I know that gets a little bit up in the sky a bit.

Yeah, it's an established framework. The citizens are used to that established framework. Here, we haven't established the framework. I mean, this goes to the point of it's not obvious that we have national health goals, a different topic. And I know that gets a little bit up in the sky a bit.

But we're at a point where what we spend and what we get for what we spend is really, really good in some ways. Obviously, not so good in other ways when you look at some of the outcomes. But many of those outcomes are not driven by the healthcare system, as we've talked about. And so the question is, where are we going to put our incremental dollars? That's the question.

But we're at a point where what we spend and what we get for what we spend is really, really good in some ways. Obviously, not so good in other ways when you look at some of the outcomes. But many of those outcomes are not driven by the healthcare system, as we've talked about. And so the question is, where are we going to put our incremental dollars? That's the question.